Literature DB >> 24284382

A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism.

G A Kline1, J L Pasieka2, A Harvey2, B So3, V C Dias4.   

Abstract

We hypothesized aldosteronoma responsiveness to cosyntropin may be a characterizing feature that could be determined in addition to standard adrenal vein sampling (AVS) data. We reviewed an AVS database from June 2005 to October 2011 including 65 patients with confirmed primary aldosteronism (PA) who underwent AVS and, if applicable, unilateral adrenalectomy. Patients were divided into confirmed lateralized and non-lateralized groups and subgrouped by histology. Plasma aldosterone in inferior vena cava (IVC) pre- and post-cosyntropin infusion during AVS was measured. Peak aldosterone and proportional change was compared between groups. Baseline and peak IVC aldosterone was higher in lateralized patients but incremental aldosterone rise was much greater in subjects with bilateral hyperplasia. From receiver operator characteristics (ROC) analysis, the optimized diagnostic cut point of peak IVC aldosterone of >649 pmol l(-1) would have a sensitivity of 94% for surgical disease although specificity of just 59%. A 250% increase in IVC aldosterone following cosyntropin would be specific enough to exclude 87% of surgical/lateralized disease. These diagnostic capabilities are similar to other results with non-AVS tests performed for diagnosis of lateralization. Although not specific enough to replace standard AVS interpretation, a marked IVC aldosterone increase after cosyntropin during AVS is a useful additional test to diagnose non-lateralizing forms of PA. Such a calculation requires no additional expense or tests.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284382     DOI: 10.1038/jhh.2013.116

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  37 in total

1.  Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting.

Authors:  F Pizzolo; E Trabetti; P Guarini; P Mulatero; A Ciacciarelli; G S Blengio; R Corrocher; O Olivieri
Journal:  J Hum Hypertens       Date:  2005-04       Impact factor: 3.012

2.  Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Variable interpretation of adrenal vein sampling.

Authors:  Gregory A Kline; Adrian Harvey; Charlotte Jones; Michael H Hill; Benny So; Nairne Scott-Douglas; Janice L Pasieka
Journal:  Int Urol Nephrol       Date:  2008-08-12       Impact factor: 2.370

3.  Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism.

Authors:  Paolo Mulatero; Chiara Bertello; Norlela Sukor; Richard Gordon; Denis Rossato; Nicholas Daunt; David Leggett; Giulio Mengozzi; Franco Veglio; Michael Stowasser
Journal:  Hypertension       Date:  2010-02-01       Impact factor: 10.190

4.  A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism.

Authors:  Jeshen H G Lau; W C Candy Sze; Rodney H Reznek; Matthew Matson; Anju Sahdev; Robert Carpenter; Daniel M Berney; Scott A Akker; Shern L Chew; Ashley B Grossman; John P Monson; William M Drake
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

5.  The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism.

Authors:  Gian Paolo Rossi; Marlena Barisa; Bruno Allolio; Richard J Auchus; Laurence Amar; Debbie Cohen; Christoph Degenhart; Jaap Deinum; Evelyn Fischer; Richard Gordon; Ralph Kickuth; Gregory Kline; Andre Lacroix; Steven Magill; Diego Miotto; Mitsuhide Naruse; Tetsuo Nishikawa; Masao Omura; Eduardo Pimenta; Pierre-François Plouin; Marcus Quinkler; Martin Reincke; Ermanno Rossi; Lars Christian Rump; Fumitoshi Satoh; Leo Schultze Kool; Teresa Maria Seccia; Michael Stowasser; Akiyo Tanabe; Scott Trerotola; Oliver Vonend; Jiri Widimsky; Kwan-Dun Wu; Vin-Cent Wu; Achille Cesare Pessina
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

6.  Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas.

Authors:  Timothy J Burton; Isla S Mackenzie; Kottekkattu Balan; Brendan Koo; Nick Bird; Dmitri V Soloviev; Elena A B Azizan; Franklin Aigbirhio; Mark Gurnell; Morris J Brown
Journal:  J Clin Endocrinol Metab       Date:  2011-11-23       Impact factor: 5.958

7.  Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms).

Authors:  Paolo Mulatero; Davide Tizzani; Andrea Viola; Chiara Bertello; Silvia Monticone; Giulio Mengozzi; Domenica Schiavone; Tracy Ann Williams; Silvia Einaudi; Antonio La Grotta; Franco Rabbia; Franco Veglio
Journal:  Hypertension       Date:  2011-08-29       Impact factor: 10.190

Review 8.  Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature.

Authors:  Victor M Montori; William F Young
Journal:  Endocrinol Metab Clin North Am       Date:  2002-09       Impact factor: 4.741

9.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma.

Authors:  Antoine Lampron; Isabelle Bourdeau; Sylvie Oble; Ariane Godbout; Walter Schürch; Philippe Arjane; Pavel Hamet; André Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

View more
  4 in total

Review 1.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

2.  Subtype prediction of primary aldosteronism by combining aldosterone concentrations in the left adrenal vein and inferior vena cava: a multicenter collaborative study on adrenal venous sampling.

Authors:  Yuichi Fujii; Hironobu Umakoshi; Norio Wada; Takamasa Ichijo; Kohei Kamemura; Yuichi Matsuda; Tatsuya Kai; Tomikazu Fukuoka; Ryuichi Sakamoto; Atsushi Ogo; Tomoko Suzuki; Kazutaka Nanba; Mika Tsuiki; Mitsuhide Naruse
Journal:  J Hum Hypertens       Date:  2017-11-24       Impact factor: 3.012

3.  Aldosterone is Aberrantly Regulated by Various Stimuli in a High Proportion of Patients with Primary Aldosteronism.

Authors:  Matthieu St-Jean; Isabelle Bourdeau; Marc Martin; André Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

Review 4.  Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism.

Authors:  Nada El Ghorayeb; Isabelle Bourdeau; André Lacroix
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-27       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.